Chad Pecot, MD

Chad V. Pecot, MD, discusses selecting between available targeted therapies in RET-, KRAS-, and MET exon 14 skipping–mutant non–small cell lung cancer.

Chad V. Pecot, MD, discusses addressing mechanisms of resistance with new targeted therapies in non–small cell lung cancer.

Chad V. Pecot, MD, discusses the growth of actionable targets in lung cancer.

Chad Pecot, MD, assistant professor, Department of Medicine, University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, discusses the frontline standard of care in advanced squamous non–small cell lung cancer (NSCLC).

Chad Pecot, MD, assistant professor, School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses talimogene laherparepvec (T-VEC; Imlygic) in the treatment of patients with lung cancer.

Chad Pecot, MD, assistant professor, School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses promising combinations for patients with non–small cell lung cancer (NSCLC).